Stock listing
TPEx:4197 Visgeneer, Inc. (暐世) 股價
Follow Visgeneer, Inc. into a list and get an email when it puts out news.
Share price · TPEX:4197
$7.15 TWD -0.15 (-2.1%)
Close on Nov 20, 2026
- Day range
- $7.06 – $7.20 TWDNov 20, 2026
- Volume
- 46,000 sharesNov 20, 2026
- Market cap
- $215.8M TWDAt the close on Nov 20, 2026 · price × 30.18M shares outstanding
- 52-week range
- $7.06 – $22.50 TWDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $773,788 TWDMedian day 16,606 shares · 4 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TPEX:4197 · TWD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $7.15 | -0.15 | -2.1% | $7.08 | $7.20 | $7.06 | 46,000 | |
| $7.30 | -0.14 | -1.9% | $7.42 | $7.47 | $7.20 | 58,151 | |
| $7.44 | -0.34 | -4.4% | $7.44 | $7.44 | $7.44 | 0 | |
| $7.78 | +0.38 | +5.1% | $7.45 | $7.78 | $7.41 | 26,001 | |
| $7.40 | -0.37 | -4.8% | $7.41 | $7.43 | $7.40 | 18,500 | |
| $7.77 | -0.03 | -0.4% | $7.41 | $7.78 | $7.41 | 26,201 | |
| $7.80 | 0.00 | 0.0% | $7.80 | $7.80 | $7.80 | 1 | |
| $7.80 | +0.15 | +2.0% | $7.53 | $7.80 | $7.45 | 9,001 | |
| $7.65 | -0.13 | -1.7% | $7.42 | $7.65 | $7.42 | 3,350 | |
| $7.78 | +0.43 | +5.9% | $7.44 | $7.78 | $7.40 | 34,300 | |
| $7.35 | -0.68 | -8.5% | $7.80 | $7.88 | $7.30 | 94,800 | |
| $8.03 | +0.10 | +1.3% | $7.71 | $8.03 | $7.70 | 46,200 | |
| $7.93 | -0.27 | -3.3% | $7.90 | $7.94 | $7.60 | 38,600 | |
| $8.20 | -0.11 | -1.3% | $7.92 | $8.20 | $7.91 | 39,410 | |
| $8.31 | 0.00 | 0.0% | $8.31 | $8.31 | $8.31 | 0 | |
| $8.31 | 0.00 | 0.0% | $7.91 | $8.31 | $7.91 | 2,000 | |
| $8.31 | -0.14 | -1.7% | $8.27 | $8.32 | $7.92 | 34,562 | |
| $8.45 | +0.13 | +1.6% | $8.27 | $8.54 | $8.27 | 5,050 | |
| $8.32 | +0.02 | +0.2% | $8.01 | $8.32 | $8.00 | 10,000 | |
| $8.30 | 0.00 | 0.0% | $8.30 | $8.30 | $8.30 | 0 | |
| $8.30 | -0.35 | -4.0% | $8.27 | $8.30 | $8.26 | 13,380 | |
| $8.65 | +0.30 | +3.6% | $8.65 | $8.65 | $8.65 | 10 | |
| $8.35 | +0.08 | +1.0% | $8.70 | $8.70 | $8.27 | 4,700 | |
| $8.27 | -0.42 | -4.8% | $8.27 | $8.27 | $8.27 | 0 | |
| $8.69 | +0.29 | +3.5% | $8.69 | $8.69 | $8.27 | 2,233 | |
| $8.40 | 0.00 | 0.0% | $8.31 | $8.40 | $8.30 | 6,220 | |
| $8.40 | -0.10 | -1.2% | $8.42 | $8.72 | $8.31 | 211,692 | |
| $8.50 | -0.25 | -2.9% | $8.42 | $8.84 | $8.42 | 12,731 | |
| $8.75 | -0.09 | -1.0% | $8.70 | $8.78 | $8.70 | 20,001 | |
| $8.84 | +0.19 | +2.2% | $8.65 | $9.10 | $8.65 | 39,586 | |
| $8.65 | -0.40 | -4.4% | $9.05 | $9.05 | $8.60 | 59,634 | |
| $9.05 | -0.07 | -0.8% | $8.70 | $9.18 | $8.36 | 155,709 | |
| $9.12 | +0.12 | +1.3% | $9.10 | $9.14 | $8.70 | 7,103 | |
| $9.00 | -0.09 | -1.0% | $8.69 | $9.09 | $8.66 | 34,603 | |
| $9.09 | +0.19 | +2.1% | $9.00 | $9.09 | $8.69 | 11,202 | |
| $8.90 | -0.23 | -2.5% | $9.14 | $9.14 | $8.68 | 130,507 | |
| $9.13 | 0.00 | 0.0% | $9.13 | $9.13 | $8.71 | 41,163 | |
| $9.13 | 0.00 | 0.0% | $9.13 | $9.13 | $8.71 | 14,105 | |
| $9.13 | -0.13 | -1.4% | $9.31 | $9.31 | $8.55 | 103,321 | |
| $9.26 | -0.05 | -0.5% | $9.31 | $9.31 | $8.87 | 28,006 | |
| $9.31 | -0.01 | -0.1% | $9.32 | $9.32 | $8.87 | 55,506 | |
| $9.32 | +0.03 | +0.3% | $9.30 | $9.33 | $8.89 | 101,613 | |
| $9.29 | +0.05 | +0.5% | $9.25 | $9.33 | $8.87 | 16,606 | |
| $9.24 | +0.05 | +0.5% | $9.20 | $9.30 | $8.85 | 83,113 | |
| $9.19 | -0.55 | -5.6% | $9.73 | $9.73 | $8.86 | 112,669 | |
| $9.74 | -0.81 | -7.7% | $10.55 | $10.55 | $9.27 | 165,254 | |
| $10.55 | -1.65 | -13.5% | $11.70 | $11.80 | $9.96 | 405,724 | |
| $12.20 | -0.50 | -3.9% | $12.90 | $14.70 | $10.95 | 869,596 | |
| $12.70 | +2.88 | +29.3% | $9.99 | $12.95 | $9.93 | 1,138,506 | |
| $9.82 | +0.90 | +10.1% | $9.20 | $9.82 | $9.00 | 208,209 | |
| $8.92 | +0.35 | +4.1% | $8.94 | $9.36 | $8.92 | 36,103 | |
| $8.57 | 0.00 | 0.0% | $8.57 | $8.57 | $8.57 | 2,000 | |
| $8.57 | 0.00 | 0.0% | $8.17 | $8.57 | $8.17 | 6,000 | |
| $8.57 | 0.00 | 0.0% | $8.57 | $8.57 | $8.57 | 1,000 | |
| $8.57 | 0.00 | 0.0% | $8.57 | $8.57 | $8.57 | 1 | |
| $8.57 | +0.38 | +4.6% | $8.57 | $8.57 | $8.57 | 48 | |
| $8.19 | 0.00 | 0.0% | $8.19 | $8.19 | $8.19 | 6,000 | |
| $8.19 | -0.38 | -4.4% | $8.19 | $8.19 | $8.19 | 1,000 | |
| $8.57 | 0.00 | 0.0% | $8.17 | $8.57 | $8.17 | 51 | |
| $8.57 | +0.41 | +5.0% | $8.16 | $8.57 | $8.16 | 10,001 | |
| $8.16 | -0.05 | -0.6% | $8.57 | $8.57 | $8.16 | 5 | |
| $8.21 | +0.05 | +0.6% | $8.57 | $8.57 | $8.16 | 9,045 | |
| $8.16 | -0.41 | -4.8% | $8.16 | $8.16 | $8.16 | 2,000 |
Splits
3 splits since 2014 · TPEX:4197 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 21-for-20 | Split | |
| 21-for-20 | Split | |
| 11-for-10 | Split |
- Ticker
- TPEx:4197
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- TPEx
- Currency
- TWD
Visgeneer, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
Valuation
P/E 41.1× against a median of 3.7×: the highest of 3 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $263.4M TWD
- P/E
- 41.1×
- EV/sales
- 1.5×
- EV/EBITDA
- 36.6×
- Price/book
- 1.1×
- Gross margin
- 38.2%
- Operating margin
- −3.0%
- Net margin
- 2.9%
- Debt to equity
- 0.5×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Visgeneer, Inc. · TPEX:4197 | US$6.55M | US$7.99M | 41.1× | 1.5× | 36.6× | 1.1× | 2.9% | 0.5× | n/a |
| Atomo Diagnostics Ltd. · ASX:AT1 | US$7.77M | US$5.56M | n/a | 1.6× | n/a | 1.5× | −65.9% | 0.1× | n/a |
| Fusion Antibodies PLC · LSE:FAB | US$6.96M | US$6.03M | n/a | 2.2× | n/a | 3.3× | −54.4% | 0.2× | n/a |
| IDL Diagnostics AB · OMXSTO:IDLDX | US$6.83M | US$4.56M | 4.6× | 0.8× | n/a | 0.5× | 25.8% | 0.1× | n/a |
| Milton Essex S.A. · NEWCONNECT:MTN | US$6.07M | US$6.06M | n/a | 17,573× | n/a | 0.5× | n/a | 0.0× | n/a |
| iXensor Co., Ltd. · TPEX:6734 | US$6.01M | US$5.63M | n/a | 6.9× | n/a | 23.1× | −174.7% | 0.9× | n/a |
| Cizzle Biotechnology Holdings PLC · LSE:CIZ | US$5.70M | US$5.59M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| AcouSort AB · OMXSTO:ACOU | US$5.69M | US$4.76M | n/a | 6.1× | n/a | 5.9× | −140.8% | 0.0× | n/a |
| GENinCode PLC · LSE:GENI | US$5.42M | US$2.86M | n/a | 0.7× | n/a | 2.0× | −185.5% | 0.1× | n/a |
| Nanologica AB · OMXSTO:NICA | US$5.29M | US$8.67M | 2.9× | 1.6× | n/a | 0.3× | 34.9% | 0.3× | n/a |
| VivoSim Labs, Inc. · NASDAQ:VIVS | US$5.29M | −US$2.76M | n/a | −20.5× | n/a | 0.7× | n/a | 0.1× | 1.91 |
| Median of the others | US$5.85M | US$5.57M | 3.7× | 1.6× | 1.5× | −65.9% | 0.1× | 1.91 |
Team and board
Officers
| Officer | Role |
|---|---|
| Ken-Shwo Dai | Chairman & CEO |
Board
| Director | Role |
|---|---|
| Ken-Shwo Dai | Chairman & CEO |
Financials
Annual, in TWD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 179.1M | 115.8M | 148.0M | 158.0M | 165.3M | 176.0M | 152.0M | 142.5M | 157.6M | 163.0M |
| Cost of revenue | 110.7M | 62.5M | 80.5M | 90.6M | 98.0M | 113.7M | 114.6M | 104.2M | 118.3M | 94.2M |
| Gross profit | 68.4M | 53.3M | 67.5M | 67.3M | 67.3M | 62.2M | 37.4M | 38.3M | 39.3M | 68.8M |
| Research and development | 25.0M | 25.7M | 25.4M | 25.4M | 26.1M | 23.1M | 24.3M | 27.8M | 26.9M | 21.7M |
| Selling, general and administrative | 48.8M | 48.0M | 28.6M | 26.4M | 27.1M | 27.3M | 28.9M | 43.9M | 36.4M | 44.5M |
| Operating income | -5.41M | -20.5M | 3.99M | 15.2M | 3.60M | 256.0K | -30.3M | -33.5M | -24.0M | 2.59M |
| Depreciation and amortization | 12.6M | 13.7M | 17.2M | 19.2M | 15.6M | 20.4M | 20.7M | 20.6M | 20.5M | 20.7M |
| EBITDA | 7.19M | -6.80M | 21.2M | 34.4M | 19.2M | 20.7M | -9.60M | -12.9M | -3.48M | 23.3M |
| Interest expense | 2.43M | 3.25M | 3.38M | 2.90M | 2.30M | 2.89M | 2.80M | 2.98M | 0 | 0 |
| Income before tax | 5.25M | -17.7M | -19.6M | 12.3M | 1.33M | -2.43M | -31.8M | -32.6M | -33.0M | 542.0K |
| Income tax | 508.0K | -3.03M | -690.0K | -2.35M | 161.0K | |||||
| Net income | 5.25M | -17.7M | -19.6M | 12.3M | 820.0K | 603.0K | -31.8M | -31.9M | -30.7M | 381.0K |
| Earnings per share, basic | 0.17 | -0.59 | -0.65 | 0.41 | 0.03 | 0.02 | -1.05 | -1.06 | -1.02 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 69.3M | 70.4M | 127.3M | 185.3M | 88.1M | 74.4M | 147.6M | 110.8M | 180.3M | 149.8M |
| Short-term investments | 5.80M | 45.7M | 5.80M | 5.80M | ||||||
| Receivables | 22.9M | 15.1M | 14.3M | 47.2M | 45.9M | 98.0M | 43.7M | 26.8M | 53.9M | 20.9M |
| Inventory | 50.9M | 49.2M | 49.1M | 32.9M | 47.0M | 39.3M | 39.9M | 47.8M | 34.3M | 56.4M |
| Current assets | 149.4M | 140.0M | 194.8M | 268.3M | 190.6M | 217.9M | 242.3M | 195.0M | 273.3M | 233.9M |
| Property, plant and equipment | 230.0M | 215.1M | 229.2M | 244.4M | 259.9M | 274.8M | ||||
| Total assets | 335.0M | 332.1M | 397.2M | 486.7M | 427.0M | 462.0M | 480.8M | 451.2M | 547.6M | 519.5M |
| Accounts payable | 13.8M | 9.32M | 13.6M | 12.8M | 12.1M | 16.5M | 16.1M | 9.55M | 11.2M | 9.77M |
| Current liabilities | 40.5M | 33.2M | 71.3M | 97.5M | 37.5M | 72.5M | 83.4M | 22.1M | 86.6M | 37.2M |
| Long-term debt | 95.3M | 104.7M | 114.1M | 158.0M | 170.0M | 170.0M | 180.0M | 180.0M | 180.0M | 170.5M |
| Total debt | 158.6M | 230.6M | 181.5M | 212.4M | 230.0M | |||||
| Total liabilities | 135.9M | 138.2M | 185.6M | 255.6M | 208.2M | 244.0M | 263.4M | 202.1M | 266.6M | 207.8M |
| Shareholders' equity | 199.1M | 193.8M | 211.6M | 231.2M | 218.8M | 218.0M | 217.4M | 249.1M | 281.0M | 311.7M |
| Shares outstanding | 30.2M | 30.2M | 30.2M | 30.2M | 30.2M | 30.2M | 30.2M | 30.2M | 30.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 13.4M | -10.2M | 13.2M | 43.5M | 12.3M | 7.57M | -11.7M | -2.60M | -23.6M | 31.5M |
| Capital spending | -5.38M | -3.80M | -585.0K | -1.69M | -7.89M | -22.1M | -1.48M | -2.78M | -4.82M | -12.5M |
| Free cash flow | 7.98M | -14.0M | 12.6M | 41.9M | 4.45M | -14.5M | -13.2M | -5.42M | -30.5M | 19.0M |
| Cash from investing | 32.1M | -59.9M | -646.0K | -6.85M | -5.97M | -12.1M | ||||
| Cash from financing | -72.2M | 49.1M | -30.8M | -20.9M | 49.1M | -60.0M | 60.0M | 2.86M | ||
| Dividends paid | -7.14M | |||||||||
| Share buybacks | 0 | |||||||||
| Change in cash | -1.08M | -56.9M | -58.0M | 97.2M | 13.7M | -73.2M | 36.8M | -69.4M | 30.5M | 22.3M |
Cap table
Built by 6ix from Visgeneer, Inc.’s releases
- Common shares
- 30,181,000
- Fully diluted
- 30,181,000
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 30,181,000 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 30,181,000 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ken-Shwo Dai | Chairman & CEO · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Visgeneer, Inc.